PRRT2 and cancer: Bryostatin-1 (binding affinity for PKC Ki, 1.35 nM, https://pubchem.ncbi.nlm.nih.gov/compound/, accessed on 17 July 2023) competes with cancer-promoting PKC ligands such as DAG and phorbol 12-myristate 13-acetate (PMA) to bind to the C1 regulatory domain of PKC-promoting either activation (short-term exposure to the drug) or inhibition (long-term exposure to the drug) of PKC [184].